0JAV Stock Overview
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Insmed Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$74.10 |
| 52 Week High | US$84.82 |
| 52 Week Low | US$21.96 |
| Beta | 1.28 |
| 1 Month Change | -6.89% |
| 3 Month Change | 3.85% |
| 1 Year Change | 180.39% |
| 3 Year Change | 218.70% |
| 5 Year Change | n/a |
| Change since IPO | 166.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JAV | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.0% | -2.3% | -2.2% |
| 1Y | 180.4% | -11.7% | 6.8% |
Return vs Industry: 0JAV exceeded the UK Biotechs industry which returned -11.7% over the past year.
Return vs Market: 0JAV exceeded the UK Market which returned 6.8% over the past year.
Price Volatility
| 0JAV volatility | |
|---|---|
| 0JAV Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0JAV has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0JAV's weekly volatility has decreased from 15% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,271 | Will Lewis | www.insmed.com |
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.
Insmed Incorporated Fundamentals Summary
| 0JAV fundamental statistics | |
|---|---|
| Market cap | US$13.40b |
| Earnings (TTM) | -US$913.77m |
| Revenue (TTM) | US$363.71m |
37.4x
P/S Ratio-14.9x
P/E RatioIs 0JAV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JAV income statement (TTM) | |
|---|---|
| Revenue | US$363.71m |
| Cost of Revenue | US$85.74m |
| Gross Profit | US$277.97m |
| Other Expenses | US$1.19b |
| Earnings | -US$913.77m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.05 |
| Gross Margin | 76.43% |
| Net Profit Margin | -251.24% |
| Debt/Equity Ratio | 443.1% |
How did 0JAV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 00:19 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Insmed Incorporated is covered by 32 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neena Bitritto-Garg | Baird |
| Anita Dushyanth | Berenberg |
| Jason Zemansky | BofA Global Research |